CONTINGENT LICENSE. If during the Research Period Rigel ceases to do business or is unable to perform its duties and obligations as set forth in the Research Plan, whether due to insolvency, bankruptcy or any other reason, Pfizer shall have a non-exclusive license in the Area under the Rigel Technology and under Rigel Patent Rights to carry out and complete the Research Plan.
Appears in 5 contracts
Samples: Collaborative Research and License Agreement, Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc), Collaborative Research and License Agreement (Rigel Pharmaceuticals Inc)
